SPOTLIGHT: Baxter touts Alzheimer's data

Baxter International's Gammagard intravenous plasma-based treatment demonstrated an ability to improve the mental functions of patients with mild moderate Alzheimer's in a small trial. The trial hit its primary goals in a six-month study involving 24 patients. Secondary endpoints relating to beta-amyloid and anti- amyloid antibody levels were also hit. Recruitment for Phase III begins later in the year. Release